BioPharma articles

Allergan (AGN)

Allergan, Inc. (AGN)’s Board Of Directors Give Consent For Actavis PLC (ACT) Merger

Allergan, Inc. (AGN)’s Board Of Directors Give Consent For Actavis PLC (ACT) Merger

Both Allergan, Inc. (NYSE:AGN) and Actavis plc (NYSE:ACT) have come together to form one of the biggest pharmaceutical companies of the world with projected pro forma revenue of $23 billion in 2015. Under the current offer, Allergan would receive $66 billion in cash and shares of Actavis. The combined company would be able to market

Allergan (AGN)

Allergan, Inc. (NYSE:AGN) Close to $65 Billion Buyout by Actavis Plc (NYSE:ACT)

Botox maker Allergan, Inc. (NYSE:AGN) is close to completing a deal with Actavis Plc (NYSE:ACT) in a buy-out transaction amounting to about $65.5 billion. A report by Reuters, citing unnamed sources, indicates that Actavis puts Allergan shares at the range of $215 – $220, and the final price is likely to be on the higher

Walmart (WMT)

Wal-Mart Stores, Inc. (WMT) Started Low-Cost Primary Healthcare Services Which Is A Big Challenge For CVS Health Corp (CVS) and Walgreen Company (WAG)

Wal-Mart Stores, Inc. (NYSE:WMT), the leading retail store chain of the U.S., is all set to revolutionize the healthcare industry, as it did eight years ago by dropping generic prescription drug prices to $4. The retailer opened its first Walmart Care Clinic in Dalton, Ga., which would cost only $40 for a regular doctor visit.

sarepta SRPT logo

Ibio Inc (IBIO) and Sarepta Therapeutics Inc (SRPT) Are Playing Their Ebola Cards To Attract Investors

There is a new market for drug makers as Ebola becomes a real threat in West Africa and is sturdily spreading to other areas. Several pharmaceutical companies and research institutions have been working around the clock to get a reliable treatment for the virus. Sarepta Therapeutics Inc (NASDAQ:SRPT) is one such company. On Thursday, the

AbbVie Inc (ABBV)

AbbVie Inc (ABBV) Reevaluates Acquisition of Shire PLC (ADR) (SHPG) Over New U.S. Tax Rules

AbbVie Inc (NYSE:ABBV) is said to be considering withdrawing its bid for the acquisition of its UK based competitor Shire PLC (ADR) (NASDAQ:SHPG), citing new tax rules by the U.S. government. The U.S. drug firm had agreed to acquire the UK rival in a $52 billion deal. The U.S. Company said that it will have

Lakeland Industries (LAKE)

Alpha Pro Tech, Ltd. (APT) And Lakeland Industries, Inc. (LAKE) Saw Big Declines Although Protective Gear Is Likely to Reach Higher Demand

After the World Health Organization announced a slowdown in Ebola spreading, the shares of leading Ebola associated stocks including Alpha Pro Tech, Ltd. (NYSEMKT:APT) And Lakeland Industries, Inc. (NASDAQ:LAKE) plunged in the day’s trading. At the same time, demand for protective gear is likely to reach higher in near future. The shares of Alpha Pro

Lakeland Industries (LAKE)

Lakeland Industries, Inc. (LAKE), Alpha Pro Tech, Ltd. (APT), Ibio Inc (IBIO) Lead Biotech Stock Industry Amid Rising Ebola Fears in US

After having several governments under its worry-trap, Ebola has started influencing the stock market and Lakeland Industries, Inc. (NASDAQ:LAKE), Alpha Pro Tech, Ltd. (NYSEMKT:APT), Ibio Inc (NYSEMKT:IBIO) are among the primary gainers of the crisis. In the last few weeks, most of the biotech companies and biopharmaceuticals associated with Ebola products have witnessed a sharp

Lakeland Industries (LAKE)

Lakeland Industries, Inc. (LAKE) And Alpha Pro Tech, Ltd. (APT) Have Huge Potential With Their Protective Solutions For Ebola

The continued fears of Ebola have boosted the shares of companies indulged in protective clothing manufacturing. The shares of Lakeland Industries, Inc. (NASDAQ:LAKE) and Alpha Pro Tech, Ltd. (NYSEMKT:APT) witnessed an upward trend after the likeliness of heightened demand  of protective wear. The shares of Lakeland Industries, Inc. (NASDAQ:LAKE) rose up to 10.78% on Friday

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Wins FDA Approval for Hepatitis C Drug That Costs More Than $1000 a Pill

Gilead Sciences, Inc. (NASDAQ:GILD) has finally secured U.S. Food and Drug Administration’s approval for its Hepatitis C drug. The once-a-day pill is however coming into the market even pricier than Solvadi, which costs $1000 a pill. The drug, which is the first only oral full treatment for the illness is said to cost $1125. The

Herbalife (HRF)

Herbalife Ltd. (HLF) Update: Former FTC Commission Harbour Ready to Risk Neck For The Company, Says Confident About Company’s Products

After taking the post of Head of Compliance team for Herbalife Ltd. (NYSE:HLF), former FTC Chief was quite comfortable after a brief look at the company’s operations. Pamela Jones Harbour took the post with the troubled company, which is facing accusations of running a pyramid scheme. The appointment of the former FTC chief helped the